CO6990729A2 - Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3) - Google Patents

Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3)

Info

Publication number
CO6990729A2
CO6990729A2 CO14134694A CO14134694A CO6990729A2 CO 6990729 A2 CO6990729 A2 CO 6990729A2 CO 14134694 A CO14134694 A CO 14134694A CO 14134694 A CO14134694 A CO 14134694A CO 6990729 A2 CO6990729 A2 CO 6990729A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
regf
glycolyl
treatment
neugcgm3
Prior art date
Application number
CO14134694A
Other languages
English (en)
Inventor
Palomo Adys González
Perez Adriana Carr
Monzón Kalet León
Santana Rancés Blanco
Alvarez María Del Carmen Barroso
Abraham Amparo Emilia Macías
Casimiro José Enrique Montero
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47435671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6990729(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of CO6990729A2 publication Critical patent/CO6990729A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere, a composiciones farmacéuticas para el tratamiento de tumores malignos. Particularmente aquellos tumores que expresan los blancos REGF y gangliósido N-glicolil GM3 con el fin de potenciar el efecto terapéutico que producen las terapias contra dichos blancos por separado. Las composiciones farmacéuticas de la invención comprenden anticuerpos y/o vacunas contra cada uno de los blancos. Adicionalmente la presente invención se refiere a los métodos para la aplicación de las composiciones de la invención.
CO14134694A 2011-12-27 2014-06-20 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3) CO6990729A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20110245A CU24070B1 (es) 2011-12-27 2011-12-27 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)

Publications (1)

Publication Number Publication Date
CO6990729A2 true CO6990729A2 (es) 2014-07-10

Family

ID=47435671

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14134694A CO6990729A2 (es) 2011-12-27 2014-06-20 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3)

Country Status (26)

Country Link
US (1) US9790279B2 (es)
EP (1) EP2805747B1 (es)
JP (1) JP6027137B2 (es)
KR (1) KR101703637B1 (es)
CN (1) CN103998098B (es)
AR (1) AR089490A1 (es)
AU (1) AU2012361321C1 (es)
BR (1) BR112014015693B1 (es)
CA (1) CA2855182C (es)
CL (1) CL2014001236A1 (es)
CO (1) CO6990729A2 (es)
CU (1) CU24070B1 (es)
EA (1) EA030346B1 (es)
ES (1) ES2694324T3 (es)
IL (1) IL233323B (es)
MX (1) MX359476B (es)
MY (1) MY185138A (es)
PE (1) PE20142328A1 (es)
PH (1) PH12014501202A1 (es)
SG (1) SG11201403014XA (es)
TN (1) TN2014000203A1 (es)
TR (1) TR201816232T4 (es)
TW (1) TWI523663B (es)
UA (1) UA111403C2 (es)
WO (1) WO2013097834A1 (es)
ZA (1) ZA201405424B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69327620T2 (de) * 1992-08-18 2000-08-03 Centro De Immunologia Molecular, Ciudad De La Habana Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
CN1103404A (zh) * 1993-03-01 1995-06-07 分子免疫中心 识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores

Also Published As

Publication number Publication date
AR089490A1 (es) 2014-08-27
KR20140100538A (ko) 2014-08-14
BR112014015693B1 (pt) 2023-03-21
MY185138A (en) 2021-04-30
JP2015506354A (ja) 2015-03-02
TWI523663B (zh) 2016-03-01
WO2013097834A1 (es) 2013-07-04
TN2014000203A1 (en) 2015-09-30
CA2855182C (en) 2018-06-12
EA030346B1 (ru) 2018-07-31
TW201336509A (zh) 2013-09-16
UA111403C2 (uk) 2016-04-25
CU24070B1 (es) 2015-01-29
IL233323A0 (en) 2014-08-31
CN103998098B (zh) 2017-08-04
AU2012361321A1 (en) 2014-07-24
IL233323B (en) 2018-11-29
US9790279B2 (en) 2017-10-17
CN103998098A (zh) 2014-08-20
TR201816232T4 (tr) 2018-11-21
EP2805747A1 (en) 2014-11-26
ZA201405424B (en) 2016-02-24
MX2014007919A (es) 2014-07-30
US20140363494A1 (en) 2014-12-11
EP2805747B1 (en) 2018-10-17
CU20110245A7 (es) 2013-08-29
SG11201403014XA (en) 2014-09-26
NZ627012A (en) 2016-01-29
BR112014015693A8 (pt) 2017-07-04
KR101703637B1 (ko) 2017-02-07
AU2012361321A8 (en) 2014-08-07
PH12014501202A1 (en) 2014-09-08
JP6027137B2 (ja) 2016-11-16
EA201491284A1 (ru) 2014-09-30
ES2694324T3 (es) 2018-12-19
PE20142328A1 (es) 2015-01-29
MX359476B (es) 2018-09-27
AU2012361321C1 (en) 2016-03-10
AU2012361321B2 (en) 2015-11-19
CA2855182A1 (en) 2013-07-04
CL2014001236A1 (es) 2014-08-08
BR112014015693A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CU20150128A7 (es) Conjugados fármaco-anticuerpo
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
UY34347A (es) Proteínas de función dual para tratar trastornos metabólicos
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CO2017003005A2 (es) Anticuerpos anti-mfi2
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112017006779A2 (pt) composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
GB201411467D0 (en) 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
MX371343B (es) Moduladores del receptor x hepatico (lxr).
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite